<SEC-DOCUMENT>0001193125-25-225105.txt : 20250930
<SEC-HEADER>0001193125-25-225105.hdr.sgml : 20250930
<ACCEPTANCE-DATETIME>20250930163006
ACCESSION NUMBER:		0001193125-25-225105
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250926
FILED AS OF DATE:		20250930
DATE AS OF CHANGE:		20250930

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Young Teresa L.
		CENTRAL INDEX KEY:			0001814656
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37465
		FILM NUMBER:		251360916

	MAIL ADDRESS:	
		STREET 1:		C/O SERES THERAPEUTICS, INC.
		STREET 2:		SUITE 1750
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77098

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Seres Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001609809
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				274326290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617 945 9626

	MAIL ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Seres Health, Inc.
		DATE OF NAME CHANGE:	20140603
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-09-26</periodOfReport>

    <issuer>
        <issuerCik>0001609809</issuerCik>
        <issuerName>Seres Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>MCRB</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001814656</rptOwnerCik>
            <rptOwnerName>Young Teresa L.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SERES THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>101 CAMBRIDGE PARK DRIVE</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02140</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>See Remarks</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Restricted Stock Units</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-09-26</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>3998</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F2"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>3998</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>3998</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each restricted stock unit (&quot;RSU&quot;) represents a contingent right to receive one share of Issuer common stock.</footnote>
        <footnote id="F2">The RSUs will vest in a single installment on November 15, 2025, subject to the Reporting Person's satisfaction of the terms contemplated in the award agreement.The RSUs have no expiration date.</footnote>
    </footnotes>

    <remarks>EVP, Chief Commercial &amp; Strategy Officer</remarks>

    <ownerSignature>
        <signatureName>/s/ Thomas J. DesRosier, attorney-in-fact for Teresa L. Young</signatureName>
        <signatureDate>2025-09-30</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
